Atalanta Sosnoff Capital LLC Has $66.17 Million Holdings in Boston Scientific Co. (NYSE:BSX)

Atalanta Sosnoff Capital LLC reduced its position in Boston Scientific Co. (NYSE:BSX - Free Report) by 3.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 740,806 shares of the medical equipment provider's stock after selling 23,038 shares during the quarter. Boston Scientific makes up 1.4% of Atalanta Sosnoff Capital LLC's portfolio, making the stock its 25th largest holding. Atalanta Sosnoff Capital LLC owned approximately 0.05% of Boston Scientific worth $66,169,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. TFC Financial Management Inc. boosted its stake in Boston Scientific by 308.8% in the 4th quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock valued at $25,000 after buying an additional 210 shares in the last quarter. West Oak Capital LLC acquired a new stake in Boston Scientific during the 4th quarter valued at $29,000. Valley National Advisers Inc. boosted its stake in Boston Scientific by 262.4% in the fourth quarter. Valley National Advisers Inc. now owns 395 shares of the medical equipment provider's stock worth $35,000 after purchasing an additional 286 shares in the last quarter. Fairway Wealth LLC bought a new position in shares of Boston Scientific in the fourth quarter valued at about $36,000. Finally, Global Trust Asset Management LLC increased its position in Boston Scientific by 64.5% in the 4th quarter. Global Trust Asset Management LLC now owns 436 shares of the medical equipment provider's stock valued at $39,000 after acquiring an additional 171 shares in the last quarter. Institutional investors own 89.07% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. Raymond James upped their price objective on Boston Scientific from $119.00 to $122.00 and gave the company a "strong-buy" rating in a report on Thursday, February 6th. Evercore ISI increased their price target on shares of Boston Scientific from $110.00 to $112.00 and gave the company an "outperform" rating in a research report on Thursday, April 24th. Morgan Stanley upped their target price on shares of Boston Scientific from $100.00 to $120.00 and gave the company an "overweight" rating in a research note on Thursday, February 6th. Wells Fargo & Company upped their price objective on shares of Boston Scientific from $100.00 to $118.00 and gave the company an "overweight" rating in a research report on Thursday, February 6th. Finally, UBS Group boosted their target price on Boston Scientific from $105.00 to $130.00 and gave the company a "buy" rating in a research note on Friday, February 7th. Twenty-three research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $114.52.

Insider Transactions at Boston Scientific

In other news, CEO Michael F. Mahoney sold 164,443 shares of Boston Scientific stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $102.48, for a total transaction of $16,852,118.64. Following the transaction, the chief executive officer now owns 1,535,706 shares in the company, valued at approximately $157,379,150.88. The trade was a 9.67 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Arthur C. Butcher sold 17,314 shares of Boston Scientific stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $102.06, for a total value of $1,767,066.84. Following the completion of the transaction, the executive vice president now directly owns 22,235 shares of the company's stock, valued at approximately $2,269,304.10. This trade represents a 43.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 307,025 shares of company stock valued at $31,742,060. Company insiders own 0.50% of the company's stock.

Boston Scientific Stock Performance

Shares of BSX traded down $0.16 during midday trading on Thursday, reaching $104.64. The stock had a trading volume of 1,886,648 shares, compared to its average volume of 6,324,639. The firm has a market cap of $154.81 billion, a PE ratio of 83.71, a P/E/G ratio of 2.79 and a beta of 0.68. The firm has a 50 day simple moving average of $98.73 and a 200-day simple moving average of $95.72. Boston Scientific Co. has a one year low of $71.88 and a one year high of $107.17. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts' consensus estimates of $0.67 by $0.08. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. The firm had revenue of $4.66 billion for the quarter, compared to the consensus estimate of $4.57 billion. During the same quarter in the previous year, the business earned $0.56 earnings per share. The business's revenue was up 20.9% compared to the same quarter last year. As a group, sell-side analysts anticipate that Boston Scientific Co. will post 2.85 EPS for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.